News for Absci Corporation (ABSI)

The latest figures reveal that AbSci Corp (ABSI) experienced a significant rise in its indicative borrow rate, increasing by 1.68 to reach 3.18%. This change hi

Significant Stock Transaction by Catherine Wood (Trades, Portfolio) On March 31, 2025, a notable stock transaction was executed by the esteemed market expert Ca

Some of the self-published newsletters on Substack have been getting into the “teaser” business over the past year, and one of the most-followed ones over t...

On May 14, 2025, Needham analyst Gil Blum reaffirmed their positive outlook on Absci (ABSI), reiterating a "Buy" rating for the stock. The rating status remains

Shares of Everus Construction Group, Inc. ECG rose sharply in today's pre-market trading after the company posted better-than-expected first-quarter results. E...

Revenue: $1.2 million for Q1 2025.Research and Development Expenses: $16.4 million for Q1 2025, up from $12.2 million in the prior year period.Selling, General

Absci Corporation has entered a crucial new phase with its inaugural human clinical trial for ABS-101. Wall Street analysts project a substantial upside

Absci Corporation (NASDAQ:ABSI) Q1 2025 Earnings Conference Call May 13, 2025 4:30 PM ETCompany ParticipantsAlex Khan - VP, Finance and IRSean McClain -...

Absci becomes clinical stage company with ABS-101, first AI-designed biologic for IBD, beginning Phase 1 trial Preclinical data for ABS-101 demonstrates high

Initiated dosing of participants in the first-in-human study of ABS-101 (anti-TL1A antibody), with interim data expected in the second half of 2025 ABS-2

PR NewswireTOKYO, May 7, 2025 TOKYO, May 7, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today annou

KeyBanc has revised its price target for Absci (ABSI), increasing it from $5 to $9, while maintaining an Overweight rating on the stock. This update comes as th

VANCOUVER, Wash. and NEW YORK, April 14, 2025 (GLOBE NEWSWIRE) -- Absci Corporation ( ABSI), a data-first generative AI drug creation company, today announced

**media[594887]**

Absci gained on animal testing phaseout news, but the change has limited near-term impact on its investment case. Read why ABSI stock is a hold.

FDA announces plan to end mandatory animal testing of new drugs, replacing it with more effective and human relevant methods.

The FDA has announced plans to reduce or replace animal testing in developing monoclonal antibody therapies and other drugs. This shift will utilize human-relev

U.S. stocks were lower, with the Dow Jones index dipping over 250 points on Friday. Shares of Fastenal Company FAST rose sharply during Thursday's session foll...

Absci Corporation stock has dropped since January, driven by weak earnings and broader biotech sector pressures. Learn more about ABSI stock here.